The time has come to transition to sustainable strategies centred around inclusion, innovation and integration
Karan Singh (pictured), Managing Director at ACG, says: 2023 will continue to pave the way towards sustainable manufacturing, with a growing number of organisations placing focus on creating long-term solutions.
Now is the time for new manufacturing sites to adopt and implement new technologies and to transform pharma manufacturing from being reliant on costly legacy processes.
Digital technology will speed up processes by enabling early detection of wear and tear on machinery lines. It will also help to reduce wastage and recalls by effectively tracking defective batches, allowing for timely interventions.
Placing digital "Industry 4.0" technologies – such as AI, machine learning, IoT, Augmented and Virtual Reality – at the heart of manufacturing can further improve R&D and speed up testing, compliance and efficiency.
Adopting Industry 4.0 technology and new delivery models can help to build a more self-reliant and robust pharmaceutical supply chain to keep up with changing and increasingly complex healthcare needs.
Our focus is on creating high-performing and quality driven manufacturing units that can support smart, connected, and intelligent systems. Reams of data converts into actionable intelligence, improving several supply chain aspects such as inventory management, trend analysis, forecasting and predictive equipment maintenance.
The growth of digital health technology and telemedicine will continue to drive healthcare innovations in 2023.
Developments such as medical device integrations and software monitoring will be centred around at-home and remote diagnosis, ultimately aimed at improving clinical outcomes and pre- and post-consultation care for more ‘informed’ patients.
Inclusion, innovation and integration will be keywords for the pharmaceutical industry in 2023.